Institute of Medicine Committee: FDA drug label “is irrelevant”
"It’s not a question of just knowing the risks and it’s not a question of labeling against risk. The question is how do you change behavior?"
"It’s not a question of just knowing the risks and it’s not a question of labeling against risk. The question is how do you change behavior?"
Your average car would cost $4.5 million, representing a 30,000% markup over cost, which is typical for prescription drugs.
Pharmaceutical News reports that the FDA has issued warnings about diet pills from Brazil marketed as dietary supplements, that contain Prozac and Librium.
This issue is NOT about trial lawyers, this issue is about the rights and health, and safety of ordinary citizens.
In what appears to be a re-run of the Katrina rescue disaster–The New York Times front page report provides yet another example of mindless and heartless shot gun public polices that are being tested on a vulnerable population of citizens:
Fortune Magazine confirms our report (October) that "The prospect of a bird flu outbreak may be panicking people around the globe, but it’s proving to be very good news for Defense Secretary."
Two items in today’s New York Times illustrate the contrast between what the Administration claims it’s legislative / regulatory proposals will do for health care, and what they actually do after they’ve taken effect.
Big Pharma by Jacky Law reveals that in essence, most of the pharmaceutical industry’s claims are false; it is not the drug, but the placebo effect whose potency deserves almost all of the credit for any health improvement:
FDA political appointees have embarked on a plan to divest the American consumer of the right to seek compensation for defective prescription drugs.
Internal e-mail exhorts university staff to lobby Congress for increased funds to increase number of children declared mentally ill.
The Senate Finance committee is cracking down on drug industry "educational grants" to physicians, medical associations and "patient advocacy" groups.
FDA is speeding the testing of unknown, potentially toxic products in humans (Phase I trials) without adequate pre-human tests.